Immune therapy added to chemotherapy improves pathological complete response in patients with early triple negative breast cancer, according to new results from the KEYNOTE-522 trial. Interim results from the study, which is the first phase III trial of immunotherapy in early breast cancer, also indicated an improvement in event-free survival.